Kailera Therapeutics, Inc. (KLRA)
| Market Cap | 2.90B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -148.96M |
| Shares Out | 123.68M |
| EPS (ttm) | -7,819.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 137,120 |
| Open | 23.27 |
| Previous Close | 23.51 |
| Day's Range | 22.95 - 24.32 |
| 52-Week Range | 20.87 - 28.23 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 23, 2026 |
About KLRA
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights... [Read more]
News
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
A company set up to develop Hengrui Pharma's weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the "NewCo" business model
Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity ca...
Kailera surges over 60% in Nasdaq debut as weight-loss drug race heats up
Weight-loss drug developer Kailera Therapeutics' shares surged 62.5% in their Nasdaq debut on Friday after closing a $625 million U.S. initial public offering, as Wall Street's appetite for the fast...
Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race
On Thursday, Kailera Therapeutics Inc. (NASDAQ: KLRA) priced its initial public offering of 39.06 million shares at $16.00 per share, with gross proceeds of around $625 million.
Kailera Therapeutics Announces Pricing of Initial Public Offering
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity ca...
Kailera Therapeutics files for US IPO
Kailera Therapeutics has filed for a U.S. initial public offering, it said in a filing on Friday.
Kailera Therapeutics IPO Registration Document (S-1)
Kailera Therapeutics has filed to go public with an IPO on the NASDAQ